BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Down 16.2% in November

BioLineRx Ltd. (NASDAQ:BLRX) was the recipient of a large decline in short interest in November. As of November 30th, there was short interest totalling 921,900 shares, a decline of 16.2% from the November 15th total of 1,100,000 shares. Based on an average daily trading volume, of 840,800 shares, the short-interest ratio is currently 1.1 days.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BLRX. HC Wainwright reduced their target price on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, November 25th. StockNews.com assumed coverage on shares of BioLineRx in a report on Tuesday. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On BioLineRx

Large investors have recently modified their holdings of the stock. CVI Holdings LLC bought a new stake in BioLineRx during the 2nd quarter valued at about $462,000. PVG Asset Management Corp purchased a new stake in shares of BioLineRx during the second quarter valued at approximately $70,000. Finally, Atria Investments Inc increased its position in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after acquiring an additional 29,193 shares in the last quarter. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Stock Performance

NASDAQ:BLRX remained flat at $0.22 during trading hours on Friday. The company’s stock had a trading volume of 973,980 shares, compared to its average volume of 493,844. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37. The firm has a 50-day moving average price of $0.39 and a 200-day moving average price of $0.57. BioLineRx has a 1-year low of $0.21 and a 1-year high of $1.77. The firm has a market capitalization of $17.98 million, a PE ratio of -1.02 and a beta of 1.39.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.